<?xml version="1.0" encoding="utf-8" ?><rss version="2.0" xmlns:News="http://www.bing.com/news/search?q=teva&amp;setmkt=en-US&amp;FORM=BNFD&amp;format=rss"><channel><title>teva - BingNews</title><link>http://www.bing.com/news/search?q=teva&amp;setmkt=en-US&amp;FORM=BNFD&amp;format=rss</link><description>Search results</description><image><url>http://www.bing.com/rsslogo.gif</url><title>teva</title><link>http://www.bing.com/news/search?q=teva&amp;setmkt=en-US&amp;FORM=BNFD&amp;format=rss</link></image><copyright>Copyright \xc2\xa9 2026 Microsoft. All rights reserved. These XML results may not be used, reproduced or transmitted in any manner or for any purpose other than rendering Bing results within an RSS aggregator for your personal, non-commercial use. Any other use of these results requires express written permission from Microsoft Corporation. By accessing this web page or using these results in any manner whatsoever, you agree to be bound by the foregoing restrictions.</copyright><item><title>Teva sandals, Skechers sneakers, and more comfortable shoes are on rare sale this weekend—starting at $8</title><link>http://www.bing.com/news/apiclick.aspx?ref=FexRss&amp;aid=&amp;tid=6a1204a4ce5940148a91dbf80a4c1807&amp;url=https%3a%2f%2fwww.msn.com%2fen-us%2flifestyle%2fshopping%2fteva-sandals-skechers-sneakers-and-more-comfortable-shoes-are-on-rare-sale-this-weekend-starting-at-8%2far-AA23O3r0&amp;c=10583893312889865144&amp;mkt=en-us</link><description>Score your favorites for summer.</description><pubDate>Fri, 22 May 2026 02:00:00 GMT</pubDate><News:Source>Real Simple on MSN</News:Source><News:Image>http://www.bing.com/th?id=ONUT.eodA-JLKNpR5mjRm-gT0TQ&amp;pid=News</News:Image><News:ImageSize>w={0}&amp;h={1}&amp;c=14</News:ImageSize><News:ImageMaxWidth>4207</News:ImageMaxWidth><News:ImageMaxHeight>2804</News:ImageMaxHeight></item><item><title>Teva's MAA for olanzapine LAI in schizophrenia accepted in the EU</title><link>http://www.bing.com/news/apiclick.aspx?ref=FexRss&amp;aid=&amp;tid=6a1204a4ce5940148a91dbf80a4c1807&amp;url=https%3a%2f%2fwww.msn.com%2fen-us%2fhealth%2fother%2ftevas-maa-for-olanzapine-lai-in-schizophrenia-accepted-in-the-eu%2far-AA23PONG&amp;c=14188294081518591735&amp;mkt=en-us</link><description>Teva Pharmaceutical Industries Limited TEVA announced that the European Medicines Agency (“EMA”) has accepted its marketing authorization application (“MAA”) seeking approval for olanzapine ...</description><pubDate>Fri, 22 May 2026 08:38:00 GMT</pubDate><News:Source>Zacks Investment Research on MSN</News:Source><News:Image>http://www.bing.com/th?id=ONUT.57IcBILyK0BRf8LipPZflQ&amp;pid=News</News:Image><News:ImageSize>w={0}&amp;h={1}&amp;c=14</News:ImageSize><News:ImageMaxWidth>598</News:ImageMaxWidth><News:ImageMaxHeight>412</News:ImageMaxHeight></item><item><title>The European Medicines Agency Accepts Teva’s Marketing Authorization Application for Olanzapine Long-Acting Injectable (TEV-‘749) for the Treatment of Schizophrenia in Adults</title><link>http://www.bing.com/news/apiclick.aspx?ref=FexRss&amp;aid=&amp;tid=6a1204a4ce5940148a91dbf80a4c1807&amp;url=https%3a%2f%2fmarkets.businessinsider.com%2fnews%2fstocks%2fthe-european-medicines-agency-accepts-teva-s-marketing-authorization-application-for-olanzapine-long-acting-injectable-tev--749-for-the-treatment-of-schizophrenia-in-adults-1036184551&amp;c=17197023375977949719&amp;mkt=en-us</link><description>The olanzapine long-acting injectable (TEV-’749) is designed to deliver the efficacy of olanzapine in a subcutaneous formulation1administered ...</description><pubDate>Thu, 21 May 2026 10:05:00 GMT</pubDate><News:Source>Markets Insider</News:Source></item><item><title>Teva agrees to pay $450 million to settle kickback and price-fixing allegations</title><link>http://www.bing.com/news/apiclick.aspx?ref=FexRss&amp;aid=&amp;tid=6a1204a4ce5940148a91dbf80a4c1807&amp;url=https%3a%2f%2fwww.statnews.com%2fpharmalot%2f2024%2f10%2f10%2fteva-antitrust-kickback-charities-medicare%2f&amp;c=11814893682714605200&amp;mkt=en-us</link><description>Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation and legislation. He is also the author of the morning Pharmalittle newsletter ...</description><pubDate>Wed, 09 Oct 2024 17:01:00 GMT</pubDate><News:Source>STAT</News:Source></item><item><title>Teva Pharmaceutical's Turnaround Is Working. Here's When to Buy the Stock.</title><link>http://www.bing.com/news/apiclick.aspx?ref=FexRss&amp;aid=&amp;tid=6a1204a4ce5940148a91dbf80a4c1807&amp;url=https%3a%2f%2fwww.fool.com%2finvesting%2f2026%2f04%2f27%2fshould-you-buy-teva-pharmaceutical-stock-now%2f&amp;c=7654321119068850435&amp;mkt=en-us</link><description>Teva Pharmaceutical Industries ( TEVA +1.23%) will unveil its first-quarter results this Wednesday, April 29. Many Teva trackers will be watching for validation of the company's continuing strategic ...</description><pubDate>Mon, 27 Apr 2026 18:58:00 GMT</pubDate><News:Source>The Motley Fool</News:Source><News:Image>http://www.bing.com/th?id=ONUT.WzPIsw41Fs3stp42kUtdSQ&amp;pid=News</News:Image><News:ImageSize>w={0}&amp;h={1}&amp;c=14</News:ImageSize><News:ImageMaxWidth>1200</News:ImageMaxWidth><News:ImageMaxHeight>800</News:ImageMaxHeight></item><item><title>Teva makes its first M&amp;A play in years, buying Emalex</title><link>http://www.bing.com/news/apiclick.aspx?ref=FexRss&amp;aid=&amp;tid=6a1204a4ce5940148a91dbf80a4c1807&amp;url=https%3a%2f%2fpharmaphorum.com%2fnews%2fteva-makes-its-first-ma-play-years-buying-emalex&amp;c=9909692760140830981&amp;mkt=en-us</link><description>After a hiatus of almost a decade, Teva has made a pipeline-building acquisition, buying Emalex Biosciences and its candidate therapy for Tourette's syndrome for up to $900 million.</description><pubDate>Thu, 30 Apr 2026 05:11:00 GMT</pubDate><News:Source>pharmaphorum</News:Source><News:Image>http://www.bing.com/th?id=ONUT.6szqtY4kokHFGwFLcLrs4w&amp;pid=News</News:Image><News:ImageSize>w={0}&amp;h={1}&amp;c=14</News:ImageSize><News:ImageMaxWidth>960</News:ImageMaxWidth><News:ImageMaxHeight>540</News:ImageMaxHeight></item><item><title>Teva's Allergan acquisition goes ahead</title><link>http://www.bing.com/news/apiclick.aspx?ref=FexRss&amp;aid=&amp;tid=6a1204a4ce5940148a91dbf80a4c1807&amp;url=https%3a%2f%2fpharmaphorum.com%2fnews%2ftevas-allergan-acquisition-goes-ahead&amp;c=12609851091288289452&amp;mkt=en-us</link><description>Teva’s $40.5 billion acquisition of Allergan’s generics business, formerly known as Actavis, has gone ahead as planned – and the generics mega-merger is set to impact the UK. In order to ensure ...</description><pubDate>Tue, 02 Aug 2016 17:00:00 GMT</pubDate><News:Source>pharmaphorum</News:Source></item><item><title>Fitch Upgrades Teva to Investment Grade Amid Pivot to Growth Execution</title><link>http://www.bing.com/news/apiclick.aspx?ref=FexRss&amp;aid=&amp;tid=6a1204a4ce5940148a91dbf80a4c1807&amp;url=https%3a%2f%2fmarkets.businessinsider.com%2fnews%2fstocks%2ffitch-upgrades-teva-to-investment-grade-amid-pivot-to-growth-execution-1036171335&amp;c=17373134369255217992&amp;mkt=en-us</link><description>Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Fitch Ratings Agency (“Fitch”) has raised the Company's corporate credit rating to Investment Grade BBB-, with a stable ...</description><pubDate>Mon, 18 May 2026 05:53:00 GMT</pubDate><News:Source>Markets Insider</News:Source></item><item><title>Teva (TEVA) Enters a New $700 Million Acquisition Deal</title><link>http://www.bing.com/news/apiclick.aspx?ref=FexRss&amp;aid=&amp;tid=6a1204a4ce5940148a91dbf80a4c1807&amp;url=https%3a%2f%2ffinance.yahoo.com%2fsectors%2fhealthcare%2farticles%2fteva-teva-enters-700-million-143547175.html&amp;c=2280398570849300843&amp;mkt=en-us</link><description>Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the Stocks that Billionaire Druckenmiller and Jim Cramer like. On April 29, 2026, Teva Pharmaceutical Industries Limited (NYSE:TEVA) ...</description><pubDate>Sat, 02 May 2026 08:01:00 GMT</pubDate><News:Source>Yahoo Finance</News:Source></item><item><title>FDA recalls blood pressure medicine over cancerous chemical</title><link>http://www.bing.com/news/apiclick.aspx?ref=FexRss&amp;aid=&amp;tid=6a1204a4ce5940148a91dbf80a4c1807&amp;url=https%3a%2f%2fwww.usatoday.com%2fstory%2fnews%2fhealth%2f2025%2f10%2f29%2fblood-pressure-medicine-recalled-prazosin-hydrochloride%2f86966059007%2f&amp;c=8880306233021044498&amp;mkt=en-us</link><description>More than half a million bottles of blood pressure medication are being recalled over a cancer-causing chemical connected to the prescription drug, according to the U.S. Food and Drug Administration.</description><pubDate>Wed, 29 Oct 2025 12:22:00 GMT</pubDate><News:Source>USA Today</News:Source></item><item><title>Teva chief executive to step down amid boardroom tensions</title><link>http://www.bing.com/news/apiclick.aspx?ref=FexRss&amp;aid=&amp;tid=6a1204a4ce5940148a91dbf80a4c1807&amp;url=https%3a%2f%2fwww.euro2day.gr%2fftcom_en%2farticle-ft-en%2f1150039%2fteva-chief-executive-to-step-down-amid-boardroom.html&amp;c=18284933047471508157&amp;mkt=en-us</link><description>The head of the world's largest generic drugs company is to step down, less than two years after he took on the job in an effort to turn round the company. Teva, based in Israel, said on Wednesday ...</description><pubDate>Wed, 20 May 2026 11:52:00 GMT</pubDate><News:Source>Euro2day</News:Source></item><item><title>Teva signs off $900m Emalex buyout amid strategic pipeline boosting ploy</title><link>http://www.bing.com/news/apiclick.aspx?ref=FexRss&amp;aid=&amp;tid=6a1204a4ce5940148a91dbf80a4c1807&amp;url=https%3a%2f%2fwww.msn.com%2fen-us%2fhealth%2fother%2fteva-signs-off-900m-emalex-buyout-amid-strategic-pipeline-boosting-ploy%2far-AA227civ&amp;c=10286550247344422624&amp;mkt=en-us</link><description>This deal falls under Teva’s wider strategy to prioritise strategic, financially diligent deals around de-risked, differentiated, late-stage assets.</description><pubDate>Thu, 30 Apr 2026 10:09:00 GMT</pubDate><News:Source>Pharmaceutical Technology on MSN</News:Source></item></channel></rss>